Genscript Biotech (HKG:1548) expects to swing to profit in the first half of 2025, according to a Hong Kong bourse filing Tuesday.
The biopharmaceutical company is estimating $175.4 million to $204.6 million in profit before tax, compared to a loss of $127.9 million in the year-ago period.
Genscript expects to post its financial results by the end of August.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。